RANIVISIO

उत्पाद अवलोकन

About RANIVISIO

RANIVISIO is a medication containing the active ingredient Ranibizumab, classified as Vascular Endothelial Growth Factor Inhibitor. Ranibizumab, sold under the brand name Lucentis among others, is a monoclonal antibody fragment (Fab) created from the same parent mouse antibody as bevacizumab.

Key Benefits & Uses

• Used for: 1 INDICATIONS AND USAGE NUFYMCO is indicated for the treatment of patients with: NUFYMCO, a vascular endothelial growth factor (VEGF) inhibitor, is.
• Used for: 1 ) Macular Edema Following Retinal Vein Occlusion (RVO) ( 1
• Use only as directed on the product label or by a healthcare professional.

Active Ingredient & Action

Ranibizumab, the active ingredient in RANIVISIO, belongs to the Vascular Endothelial Growth Factor Inhibitor class. 1 INDICATIONS AND USAGE NUFYMCO is indicated for the treatment of patients with: NUFYMCO, a vascular endothelial growth factor (VEGF) inhibitor, is indicated for the treatment of patients with: Neovascular (Wet) Age-Related Macular Degeneration (AMD) ( 1. 1 ) Macular Edema Following Retinal Vein Occlusion (RVO) ( 1. Inactive ingredients: not listed in source data.

Important Notes

Always read and follow the label instructions carefully before taking RANIVISIO. If you have any underlying medical conditions, are taking other medicines, or are pregnant or breastfeeding, consult a doctor or pharmacist before use. Do not exceed the recommended dose on the package and do not use RANIVISIO for extended periods without medical advice.